⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961837 | 0.80 | TSHR (0.42) | — | |
| SCHEMBL18292088 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL7067157 | 0.73 | ANPEP (0.31) | — | |
| SCHEMBL30287366 | 0.73 | — | — | |
| SCHEMBL7637234 | 0.67 | — | — | |
| SCHEMBL12927346 | 0.63 | — | — | |
| SCHEMBL96153 | 0.60 | — | — | |
| SCHEMBL7357250 | 0.60 | — | — | |
| SCHEMBL13857690 | 0.60 | — | — | |
| SCHEMBL3870404 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117638083-B | Lithium ion battery and electronic device | 宁德新能源科技有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117638083-A | Lithium ion battery and electronic device | 宁德新能源科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-115763968-A | Electrolyte and lithium ion battery | 广州天赐高新材料股份有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115714204-A | Electrolyte and lithium ion battery | 广州天赐高新材料股份有限公司 | 2023-02-24 | — | — | CN | claimed |
| US-20080234229-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | claimed |
| US-20080221069-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | claimed |
| WO-2007028104-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| WO-2007022437-A2 | THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND METABOLIC DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2025-12-23 | — | — | US | disclosed |
| EP-4642784-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| EP-4615523-A1 | COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2025-09-17 | — | — | EP | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-1056751-A4 | BORONIC COMPOUNDS | COMMW SCIENT IND RES ORG (AU) | 2003-01-22 | — | — | EP | disclosed |
| EP-1121365-A4 | ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS | COMMW SCIENT IND RES ORG (AU) | 2002-03-06 | — | — | EP | disclosed |
| EP-1121365-A1 | ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-08 | — | — | EP | disclosed |
| EP-1056751-A1 | BORONIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000021966-A1 | ORGANOBORON DERIVATIVES AND PROCESS FOR COUPLING ORGANIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999033845-A1 | BORONIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-07-08 | — | — | WO | disclosed |